Status:

UNKNOWN

The Efficacy and Safety of a Latest Dural Substitute

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions:

Cerebrospinal Fluid Leak

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

This prospective, multi-center, randomized, parallel-controlled clinical trial was designed to evaluate the efficacy and safety of Lyoplant Onlay in repairing cerebral dura mater. DURAFORM was regarde...

Eligibility Criteria

Inclusion

  • Any patient between the ages of 18 and 75 years scheduled for elective cranial surgery involving a dural incision.
  • Dural defects and surgical incision was classifed as level 1

Exclusion

  • local or systemic infection.
  • patients with known allergy to Equipment components
  • a history of traumatic head injury
  • a compromised immune system or autoimmune disease
  • patients who should not participate based on the surgeon's opinion
  • patients participating in any other drug or device trial.
  • expected survival time \<12 months
  • underwent chemoradiotherapy 3 months before randomization
  • uncontrolled diabetes and malignant tumor
  • women who were pregnant, lactating, or wished to become pregnant during the study;

Key Trial Info

Start Date :

November 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2021

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT04490629

Start Date

November 1 2019

End Date

November 1 2021

Last Update

July 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jianmin Zhang

Hangzhou, Zhejiang, China, 310000